Completed
Extended Buprenorphine Dosing Interval for Patient Feasibility
What is being tested
Data Collection
Who is being recruted
Narcotic-Related Disorders+2
+ Mental Disorders
+ Opioid-Related Disorders
From 21 to 50 Years
+10 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Study Start: November 1992
Summary
Principal SponsorNational Institute on Drug Abuse (NIDA)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: November 1, 1992
Actual date on which the first participant was enrolled.This study focuses on individuals who are currently maintaining their buprenorphine treatment well. The main goal is to investigate if it's possible to extend the time between doses, specifically to 48 and 72 hours. This could potentially lead to a dosing schedule of just three times a week. The significance of this study lies in its potential to simplify treatment plans, making them more manageable for those dealing with opiate dependence and cravings.
Official TitleBuprenorphine Dosing Interval
Principal SponsorNational Institute on Drug Abuse (NIDA)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 21 to 50 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Narcotic-Related DisordersMental DisordersOpioid-Related DisordersSubstance-Related DisordersChemically-Induced Disorders
Criteria
4 inclusion criteria required to participate
M/F ages 21-50.
Opiate dependence according to DSM-IV criteria.
Self-reported use within the last 30 days.
Agreeable to conditions of study and signed informed consent.
6 exclusion criteria prevent from participating
Psychiatric disorder that requires medication therapy.
History of seizures.
Pregnant and/or nursing women.
Dependence on ETOH or benzodiazepines or other sedative-hynotics.
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center